Cardiomyopathy Market 2022-2028

Description

List of Tables

Title:Global Cardiomyopathy Market Size, Share & Trends Analysis Report By Type (Dilated Cardiomyopathy, Restrictive Cardiomyopathy, Unclassified Cardiomyopathy, Hypertrophic Cardiomyopathy, and Arrhythmogenic Right Ventricular Dysplasia), By Diagnosis Test (Blood Tests, Cardiac MRI, Chest X-Ray, Cardiac CT Scan, Echocardiogram, Treadmill Stress Test, Electrocardiogram (ECG), Cardiac Catheterization, Genetic Testing Or Screening) by Treatment (Medication, Surgically Implanted Devices, Nonsurgical Procedures, Surgery) and by End-User (Homecare, Hospitals and Clinics, Diagnostic Center, and Other) Forecast Period (2022-2028).

The global cardiomyopathy market is anticipated to grow at a substantial CAGR of 4.2% during the forecast period. The increasing trend of minimally invasive surgery and the availability of remote patient monitoring technology are anticipated to contribute to the growth of the market. This new innovative technology is receiving popularity among surgeons and patients due to several benefits offered by the technology that is great for the market such as reduced recovery time, reduced pain, and low risk of post-surgery trauma.

The global cardiomyopathy market is segmented on the basis of type, diagnosis test, treatment, and end user. On the basis of type, the market is sub-divided into dilated cardiomyopathy, restrictive cardiomyopathy, unclassified cardiomyopathy, hypertrophic cardiomyopathy, and arrhythmogenic right ventricular dysplasia. Based on the diagnosis type the market is bifurcated into blood tests, cardiac MRI, chest x-ray, cardiac CT scan, echocardiogram, treadmill stress test, electrocardiogram (ECG), cardiac catheterization, genetic testing or screening. By treatment, the market is sub-categorized into medication, surgically implanted devices, nonsurgical procedures, and surgery. By end-user, the market is sub-classified into homecare, hospitals and clinics, diagnostic centers, and others. Among the diagnosis test segment, the echocardiogram sub-segment is dominating owing to being highly preferred by professional doctors in cardiomyopathy procedures. Additionally, as this is the main test in the diagnosis of cardiomyopathy due it sound waves present in it produce all the images in motion that are helpful to identify the problems and also show how blood is moving and can tell right or left ventricle is enlarged due to this testing procedure offer clear and high-resolution images and outputs it is dominating and driving the market growth.

Geographically market is segmented into: North America, Europe, Asia-Pacific, and the Rest of the World. North America in the cardiomyopathy market is holding a prominent share due to the availability in the region such as- of research funds from public and private sectors, of state-of-art technologies. Furthermore, the presence of key market players in the region, and favorable reimbursements for cardiomyopathy medications by the government and private sectors. In addition, Increasing focus on precision medicine, and growing awareness about the side effect of free medications, are factors that are contributing to and driving the market growth region.

The competitive landscape includes key strategies of leading players, recent developments, and key company analysis. The major players that contribute to the growth of the market include- Becton and Dickson & Co., Boston Scientific Corp., Mylan N.V, Pfizer, Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd., and many others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in August 2020, Cytokinetics Inc., has partnered with HCM Registry to improve the prediction of risk and outcomes in hypertrophic cardiomyopathy (HCM). The company has granted a $1 million and four-year partnership with the HCM Registry.

Research Methodology

The market study of the global cardiomyopathy market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

Financial reports of companies involved in the market.

Whitepapers, research papers, and news blogs.

Company websites and their product catalog.

The report provides an in-depth analysis of the market size, and size and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

Global Cardiomyopathy Market Research and Analysis by Type
Global Cardiomyopathy Market Research and Analysis by Diagnosis Test
Global Cardiomyopathy Market Research and Analysis by Treatment
Global Cardiomyopathy Market Research and Analysis by End-User

The Report Covers:

Comprehensive research methodology of the global cardiomyopathy market.
This report also includes a detailed and extensive market overview with key analyst insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global cardiomyopathy market.
Insights about market determinants that are stimulating the global cardiomyopathy market.
Detailed and extensive market segments with the regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.

Product Code: OMR2026605

1. Report Summary

Current TYPE Analysis and Growth Potential Outlook
Impact of COVID-19 on the Global Cardiomyopathy Market
Recovery Scenario of Global Cardiomyopathy Market
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. BY Region

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key Company Analysis
- 3.1.1. Overview
- 3.1.2. Financial Analysis
- 3.1.3. SWOT Analysis
- 3.1.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of Covid-19 on Key Players

4. Market Segmentation

4.1. Global Cardiomyopathy Market by Type
- 4.1.1. Dilated Cardiomyopathy
- 4.1.2. Restrictive Cardiomyopathy
- 4.1.3. Unclassified Cardiomyopathy
- 4.1.4. Hypertrophic Cardiomyopathy
- 4.1.5. Arrhythmogenic Right Ventricular Dysplasia
4.2. Global Cardiomyopathy Market by Diagnosis Test
- 4.2.1. Blood Tests
- 4.2.2. Cardiac MRI
- 4.2.3. Chest X-Ray
- 4.2.4. Cardiac CT Scan
- 4.2.5. Echocardiogram
- 4.2.6. Treadmill Stress Test
- 4.2.7. Electrocardiogram (Ecg)
- 4.2.8. Cardiac Catheterization
- 4.2.9. Genetic Testing Or Screening
4.3. Global Cardiomyopathy Market by Treatment
- 4.3.1. Medication
- 4.3.2. Nonsurgical Procedures
  - 4.3.2.1. Septal Ablation
  - 4.3.2.2. Radiofrequency Ablation
- 4.3.3. Surgery
  - 4.3.3.1. Septal Myectomy
  - 4.3.3.2. Heart Transplant
4.4. Global Cardiomyopathy Market by End-User
- 4.4.1. Homecare
- 4.4.2. Hospitals And Clinics
- 4.4.3. Diagnostic Center
- 4.4.4. Other

5. Regional Analysis

5.1. North America
- 5.1.1. US
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. South Korea
- 5.3.5. Rest of Asia-Pacific
5.4. Rest of the World

6. Company Profiles

6.1. Abbott
6.2. AstraZeneca
6.3. Becton, Dickinson and Co.
6.4. BIOMERIEUX, INC.
6.5. Bio-Rad Laboratories, Inc
6.6. Boston Scientific Corp.
6.7. Bristol-Myers Squibb Co.
6.8. F. Hoffmann-La Roche Ltd
6.9. Ionis Pharmaceuticals
6.10. Janssen Pharmaceuticals, Inc.
6.11. Laboratory Corp.
6.12. Medtronic Plc.
6.13. Merck & Co., Inc.
6.14. Mylan N.V.
6.15. Novartis International AG
6.16. PerkinElmer
6.17. Pfizer Inc.
6.18. Randox Laboratories
6.19. Response Biomedical Corp.
6.20. Sanofi S.A
6.21. Siemens Healthcare GmbH
6.22. Takeda Pharmaceutical Co. Ltd.
6.23. Teva Pharmaceutical Industries Ltd.
6.24. Thermo Fisher Scientific Inc.
6.25. Vericel Corp.